Please use this identifier to cite or link to this item: https://doi.org/10.1074/jbc.M112.359950
Title: Fenretinide prevents lipid-induced insulin resistance by blocking ceramide biosynthesis
Authors: Bikman, B.T.
Guan, Y.
Shui, G. 
Siddique, M.M. 
Holland, W.L.
Kim, J.Y.
Fabriàs, G.
Wenk, M.R.
Summers, S.A.
Issue Date: 18-May-2012
Source: Bikman, B.T., Guan, Y., Shui, G., Siddique, M.M., Holland, W.L., Kim, J.Y., Fabriàs, G., Wenk, M.R., Summers, S.A. (2012-05-18). Fenretinide prevents lipid-induced insulin resistance by blocking ceramide biosynthesis. Journal of Biological Chemistry 287 (21) : 17426-17437. ScholarBank@NUS Repository. https://doi.org/10.1074/jbc.M112.359950
Abstract: Fenretinide is a synthetic retinoid that is being tested in clinical trials for the treatment of breast cancer and insulin resistance, but its mechanism of action has been elusive. Recent in vitro data indicate that fenretinide inhibits dihydroceramide desaturase, an enzyme involved in the biosynthesis of lipotoxic ceramides that antagonize insulin action. Because of this finding, we assessed whether fenretinide could improve insulin sensitivity and glucose homeostasis in vitro and in vivo by controlling ceramide production. The effect of fenretinide on insulin action and the cellular lipidome was assessed in a number of lipid-challenged models including cultured myotubes and isolated muscles strips incubated with exogenous fatty acids and mice fed a high-fat diet. Insulin action was evaluated in the various models by measuring glucose uptake or disposal and the activation of Akt/PKB, a serine/threonine kinase that is obligate for insulin-stimulated anabolism. The effects of fenretinide on cellular lipid levels were assessed by LC-MS/MS. Fenretinide negated lipid-induced insulin resistance in each of the model systems assayed. Simultaneously, the drug depleted cells of ceramide, while promoting the accumulation of the precursor dihydroceramide, a substrate for the reaction catalyzed by Des1. These data suggest that fenretinide improves insulin sensitivity, at least in part, by inhibiting Des1 and suggest that therapeutics targeting this enzyme may be a viable therapeutic means for normalizing glucose homeostasis in the overweight and diabetic. © 2012 by The American Society for Biochemistry and Molecular Biology, Inc.
Source Title: Journal of Biological Chemistry
URI: http://scholarbank.nus.edu.sg/handle/10635/53434
ISSN: 00219258
DOI: 10.1074/jbc.M112.359950
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

41
checked on Dec 6, 2017

WEB OF SCIENCETM
Citations

42
checked on Nov 22, 2017

Page view(s)

42
checked on Dec 10, 2017

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.